Larysa B. Bondarenko, Ganna M. Shayakhmetova, Anatoliy V. Matvienko and Valentina M. Kovalenko
oxygen species. Curr Diabetes Rev 4:46-54, 2008.
4. Agbaje IM, Rogers DA, McVicar CM et al. I nsulin dependent diabetes mellitus: implications for male reproductive function. Hum Reprod 22: 1871-1877, 2007.
5. Nieto N, Friedman SL, Cederbaum AI. Cytochrome P450 2E1-derived reactive oxygen species mediate paracrine stimulation of collagen I protein synthesis by hepatic stellate cells. J Biol Chem 277: 9853-9864, 2002.
6. Lehti T M, Silvennoinen M, Kivela R et al. Effects of streptozotocin-induced diabetes and
, Lamia KA, Vasquez D et al. The kinase lkb1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310: 1642-1646, 2005.
46. Pawelczyk L, Spaczynski RZ, Banaszewska B, Duleba AJ. Metformin therapy increases insulin-like growth factor binding protein-1 in hyperinsulinemic women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 113: 209-213, 2004.
47. Ning J, Clemmons DR. Amp-activated protein kinase inhibits igf-i signaling and protein synthesis in vascular smooth muscle cells via stimulation of
Ganna M. Shayakhmetova, Larysa B. Bondarenko, Anatoliy V. Matvienko and Valentina M. Kovalenko
. Takasu N, Komiya I, Asawa T, Nagasawa Y, Yamada T. Streptozotocin- and alloxan-induced H 2 O 2 generation and DNA fragmentation in pancreatic islets. H 2 O 2 as mediator for DNA fragmentation. Diabetes 40: 1141-1145, 1991.
40. Bolzan AD, Bianchi MS. Genotoxicity of streptozotocin. Mutat Res 512: 121-134, 2002.
41. Bhide SV, Bhalerao EB, Sarode AV, Maru GB. Mutagenicity and carcinogenicity of mono- and diacetyl hydrazine. Cancer Lett 23: 235-240, 1984.
42. Braun R, Jakel HP, Schoneich J. Genetic effects of
Daniela Maria Hurjui, Otilia Niţă, Lidia Iuliana Graur, Dana Ştefana Popescu, Laura Mihalache, Cătălin Ilie Huţanaşu and Mariana Graur
Non-alcoholic fatty liver disease (NAFLD) is closely associated with all features ofthe metabolic syndrome (MS). This strongly supports the notion that NAFLD may bethe hepatic manifestation of the MS. NAFLD is currently the most common cause ofabnormal liver function tests and affects approximatively 15-25% of the generalpopulation. NAFLD covers a spectrum of liver disease, from steatosis to nonalcoholicsteatohepatitis (NASH) and cirrhosis. Insulin resistance (IR) has centraletiologic roles in the development of MS and NAFLD, usually related to obesity. MSis frequently associated with chronic inflammation, having as principal mediatorsthe adipocytokines and free fatty acids (FFA), but also CRP, TNF-a and IL-6.Chronic inflammation results in more IR and lipolysis of adipose tissue triglyceridestores, in enhanced hepatic glucose and VLDL production. The steatotic liver isthought to be vulnerable to secondary injuries including adipocytokines,mitochondrial dysfunctions, oxidative stress which lead to hepatocellularinflammation and fibrosis.
Tetiana Ashcheulova, Oksana Kochubiei, Ganna Demydenko, Nina Gerasimchuk and Alla Maliy
Background and aims: Essential hypertension and type 2 diabetes mellitus possess some common pathogenetic components, in particular, activation of immune inflammatory response, the intercellular mediators of which are cytokines. In our study, hypertensive patients were examined, depending on presence of concomitant prediabetes or type 2 diabetes mellitus, for the level of pro-inflammatory cytokines oncostatin M, interleukin-6 in conjunction with glucometabolic parameters and lipid metabolism parameters.
Material and methods: A total of 94 hypertensive patients were examined. Oncostatin M and Interleukin-6 plasma level detected using ELISA (BSM).
Results and conclusions: The 1st group consisted of hypertensive patients. The 2nd group included hypertensive patients with prediabetes. The 3rd group were hypertensive patients with type 2 diabetes mellitus. We have revealed the increased circulating level of oncostatin M and interleukin-6 in patients 1st group, which confirms the pathogenetic value of hypertension as a stimulus for hyperproduction of these cytokines. In 2nd group the level of oncostatin M and interleukin-6 decreased, which could probably be explained, on the one hand, by dual effects of the family of interleukin-6 the representatives of which either contribute to the development of insulin resistance or, vice versa, enhance the insulin sensitivity of tissues.
Nessrine Samira Karaouzene, Hafida Merzouk, Amel Saidi Merzouk, Samira Bouanane, Lotfi Loudjedi and Sid Ahmed Merzouk
Background and aims: Interaction between oxidative stress and inflammation has not been comprehensively investigated in the association obesity – diabetes - hypertension. Our aim was to investigate interrelations between inflammatory and oxidative stress biomarkers in obese women with two complications (hypertension, type 2 diabetes).
Material and Methods: 54 obese patients without complications, 46 diabetic patients with obesity, 48 hypertensive diabetic obese women, and 120 healthy controls were recruited from the department of nuclear medicine (Algeria). Inflammatory and oxidative stress biomarkers were assayed by appropriate methods.
Results: Inflammatory markers were significantly higher in all obese groups compared to controls. Elevated pro-oxidants and decreased antioxidant markers were noted in obese women. These alterations were accentuated when obesity was associated with hypertension and diabetes. A positive interrelationship between inflammatory mediators and oxidative status, and a negative one with antioxidants were noted during obesity. Hypertension and diabetes enhanced these correlations. Leptin, C-reactive protein, catalase, superoxide dismutase, ion superoxide, peroxynitrite were found to be the best inflammatory and oxidative stress biomarkers that can predict diabetes and hypertension in obese women.
Conclusions: oxidative stress and inflammation were intimately interconnected in women obesity associated with diabetes and hypertension.
Background and Aims: Comparative estimation of metabolic syndrome (MS) mediated changes of blood, cardio-vascular system, liver, pancreas and kidneys morphologic structure in adult and pubertal rats. Materials and Methods: Wistar albino male rats of two age categories (young animals of 21 days age (50-70g) and adults (160-180g)) were divided into 4 groups (8 animals in each): 1 - Control 1 (intact young rats); 2 - Control 2 (intact adult rats); 3 - MS3 (young rats with MS) and 4 - MS4 (adult rats with MS). The metabolic syndrome model was induced by full replacement of drinking water with 20% fructose solution (200g/l). After 60 days of MS modeling, determination of rat hematological and serum biochemical parameters, glucose tolerance, blood pressure, liver rates of lipid peroxydation and chromatin DNA fragmentation, as well as morphological macroscopic and microscopic studies were carried out. Results: In pubertal rats, glucose tolerance, hypertension, blood clotting disturbances, DNAfragmentation and lipid peroxydation rates were affected more profoundly, while mature rats showed greater Pseudo Pelger-Huet anomaly development, serum cholesterol and lipoproteins increases, liver and kidney morphology changes. Conclusions: Our current data combined with previous results of other authors allow us to conclude that an animal model (Wistar rats) of MS is quite easily obtained in a full age range, from juvenile to mature rats.
Andra-Iulia Suceveanu, Laura Mazilu, Doina Catrinoiu, Adrian-Paul Suceveanu, Felix Voinea and Irinel-Raluca Parepa
somatotropic axis in healthy non-diabetic elderly men. Eur J Endocrinol 155: 167-176, 2006.
10. Kamada Y, Matsumoto H, Tamura S et al . Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J Hepatol 47: 556-564, 2007.
11. Bråkenhielm E, Veitonmäki N, Cao R et al . Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA 101: 2476-2481, 2004.
12. Tsochatzis EA, Papatheodoridis GV, Archimandritis
Anca Jivanescu, Luciana Goguta, Armina Stemper, Raul Rotar and Luminita Nica
37(1): 9-16, 2010.
11. Vergnes JN, Canceill T, Vinel A et al. The effects of periodontal treatment on diabetic patients: the DIAPERIO randomized controlled trial. J Clin Periodontol 45(10): 1150-1163, 2018
12. Novotna M, Podzimek S, Broukal Z, et al. Periodontal diseases and dental caries in children with type1 diabetes mellitus. Mediators Inflamm 2015:379626, 2015.
13. Lundgren D. Prosthetic reconstruction of dentitions seriously compromised by periodontal disease. J Clin Periodontol 18: 390-395, 1991